Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.

  • Hernández-Muñoz, Inmaculada
  • Figuerola, Elisabeth
  • Sánchez-Molina, Sara
  • Rodríguez García, Eva
  • Fernández Mariño, Ana Isabel, 1984-
  • Pardo-Pastor, Carlos
  • Bahamonde Santos, María Isabel, 1972-
  • Fernández-Fernández, José Manuel, 1967-
  • García-Domínguez, Daniel J.
  • Hontecillas-Prieto, Lourdes
  • Lavarino, Cinzia
  • Carcaboso, Angel M.
  • Torres, Carmen de
  • Tirado, Oscar M.
  • Alava, Enrique de
  • Mora, Jaume
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MECFEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014- 2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7- HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIIIFEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG- 08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

  • Kager, Leo
  • Whelan, Jeremy
  • Dirksen, Uta
  • Hassan, Bass
  • Anninga, Jakob
  • Bennister, Lindsey
  • Bovée, Judith V. M. G.
  • Brennan, Bernadette
  • Broto, Javier Martín
  • Brugières, Laurence
  • Cleton-Jansen, Anne-Marie
  • Copland, Christopher
  • Dutour, Aurélie
  • Fagioli, Franca
  • Ferrari, Stefano
  • Fiocco, Marta
  • Fleuren, Emmy
  • Gaspar, Nathalie
  • Gelderblom, Hans
  • Gerrand, Craig
  • Gerß, Joachim
  • Gonzato, Ornella
  • van der Graaf, Winette
  • Hecker-Nolting, Stefanie
  • Herrero Martín, David
  • Klco-Brosius, Stephanie
  • Kovar, Heinrich
  • Ladenstein, Ruth
  • Lancia, Carlo
  • LeDeley, Marie-Cecile
  • McCabe, Martin G.
  • Metzler, Markus
  • Myklebost, Ola
  • Nathrath, Michaela
  • Picci, Piero
  • Potratz, Jenny
  • Redini, Françoise
  • Richter, Günther H. S.
  • Reinke, Denise
  • Rutkowski, Piotr
  • Scotlandi, Katia
  • Strauss, Sandra
  • Thomas, David
  • Tirado, Oscar M.
  • Tirode, Franck
  • Vassal, Gilles
  • Bielack, Stefan S.
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

  • Mackintosh, Carlos
  • García-Domínguez, D. J.
  • Ordóñez, José Luis
  • Ginel-Picardo, Alicia
  • Smith, P. G.
  • Sacristán, María P.
  • Álava, Enrique de
Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of children and young adults in which finding effective new targeted therapies is imperative. Here, we report an in-depth preclinical study of the investigational cullin-RING ubiquitin ligase (CRL) inhibitor MLN4924 in ES, as we have recently demonstrated the implication of a CRL component in the ES pathogenesis. First, our results support a high sensitivity of ES cells to MLN4924 growth inhibition both in vitro (14 ES cell lines tested, median IC50=81 nM) and in tumor xenografts (tumor regression achieved with 60 mg/kg BID, subcutaneously, n=9). Second, we report a dual mechanism of action of MLN4924 in ES cells: while a wide range of MLN4924 concentrations (∼30-300 nM) trigger a G2 arrest that can only be rescued by WEE1 kinase inhibition or depletion, saturating doses of the drug (>300 nM) cause a delay in S-phase progression concomitant with unbalanced CDK2-Cyclin E and CDK2-Cyclin A relative levels (accumulation of the first and depletion of the latter). The aberrant presence of CDC6 in the nucleus at late S-phase cell cycle stage confirmed the loss of CDK2-Cyclin A-specific functions. Remarkably, other mechanisms explored (P27 accumulation and DNA damage signaling pathways) were found unable to explain MLN4924 effects, strengthening the specificity of our findings and suggesting the absence of functionality of some CRL substrates accumulated in response to MLN4924. This study renders a rationale for clinical trials and contributes molecular mechanisms for a better understanding of this promising antitumoral agent., Daniel J García-Domínguez is supported by a grant from the María García Estrada Foundation. Research in Enrique de Alava’s lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (PI081828, RD06/0020/0059, PI1100018, ISCIII_postdoc grant CD06/00001) and the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

  • Ordóñez, José Luis
  • Amaral, Ana Teresa
  • Herrero-Martín, David
  • García-Macías, Carmen
  • Sevillano, Victoria
  • San-Segundo, Laura
  • Fraile, Susana
  • Teodosio, Cristina
  • Tirado, Óscar M.
  • Mora, Jaume
  • Álava, Enrique de
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al., Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage. Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh disrupts the DDR machinery. Thus, given the impact and apparent specificity of both agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in ES, we decided to explore the activity of combining PARPinh and Trabectedin in in vitro and in vivo experiments. The combination of Olaparib and Trabectedin was found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear accumulation as a result of DNA damage induction, DNA fragmentation and global DDR deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of the drug combination was corroborated in a mouse xenograft model of ES and, more importantly, in two ES patient-derived xenograft (PDX) models in which the tumors showed complete regression. In conclusion, the combination of the two agents leads to a biologically significant deregulation of the DDR machinery that elicits relevant antitumor activity in preclinical models and might represent a promising therapeutic tool that should be further explored for translation to the clinical setting., Enrique de Álava’s lab is supported by the AECC (Asociación Española Contra el Cáncer), the Ministry of Economy and Competitiveness of Spain-FEDER (PI081828, RD06/0020/0059 RD12/0036/0017, PT13/0010/0056, PI110018, ISCIII Sara Borrell postdoc grant CD06/00001), the European Project EuroSARC (FP7-HEALTH-2011- two-stage, Project ID 278742 EUROSARC), Fundación Memoria de D. Manuel Solorzano Barruso, Fundación Cris contra el cancer, and Fundación María García Estrada. JLO was sponsored by the CSIC and the European Social Fund (post-doctoral grant JAE DOC) and is at present funded by the AECC. ATA is sponsored by the Fundaçao para a Ciência e Tecnologia, Portugal (fellowship SFRH/BD/69318/2010). OMT is funded by Fondo de Investigaciones Sanitarias-ISCIII (CES12/021) and the AECC. DHM is funded by the AECC. Work supported by the Xarxa de Bancs de Tumors de Catalunya (XBTC) sponsored by Pla Director d’Oncologia de Catalunya. AMC acknowledges funding from the European Union Seventh Framework Programme (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG-08- GA-2010-276998) and ISCIII-FEDER (CP13/00189)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Infections shared with wildlife: an updated perspective

  • Gortázar, Christian
  • Ruiz-Fons, Francisco
  • Höfle, Ursula
Infections shared with wildlife matter because many are zoonotic, because of their impact on animal health and in consequence on livestock production, and due to their adverse effects on conservation and on the sustainable use of wildlife. We describe recent environmental and societal changes that contribute to explain the current wildlife disease scenario, propose an updated list and ranking of relevant shared disease agents, illustrate key risk factors which often underlay shared infections, and provide a summary of recent progress in wildlife monitoring and disease control. We conclude, first, that there is a need for a better understanding of population dynamics and for good baseline data on wildlife population trends. Also, there is a need to adapt our wildlife management and disease control strategies to a context of growing conflicts and increasing social complexity. Second, a few pathogens appear consistently in the rankings of relevant shared diseases and tend to receive most attention from the scientific community. However, most current research on wildlife diseases is still descriptive. Therefore, a deeper understanding of disease ecology and progress in risk factor identification is needed. Third, interventions regarding wildlife diseases are rarely widespread and not necessarily successful, and three aspects need urgent regulation in order to improve wildlife health: wildlife feeding, disease control in farmed or translocated wildlife, and hunting offal disposal. While the drivers of disease emergence are still active, awareness is also growing in governmental and supra-governmental agencies, farmers, and the academy, contributing to create a fertile ground for future innovative disease control efforts., Research funding is acknowledged to Plan Nacional grant AGL2014-56305 (MINECO, Spain and FEDER) and the EU FP7 grants ANTIGONE no. 278976 and H2020 grant COMPARE no. 377/14. FRF acknowledges a Ramón y Cajal contract from MINECO, Spain., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications

  • Amaral, Ana Teresa
  • Biscuola, Michele
  • López-García, María Ángeles
  • Álava, Enrique de
Amaral, Ana Teresa et al., [Background] Ewing Sarcoma (EWS) is a mesenchymal-derived tumor that generally arises in bone and soft tissue. Intensive research regarding the pathogenesis of EWS has been insufficient to pinpoint the early events of Ewing sarcomagenesis. However, the Mesenchymal Stem Cell (MSC) is currently accepted as the most probable cell of origin., [Materials and Methods] In an initial study regarding a deep characterization of MSC obtained specifically from EWS patients (MSC-P), we compared them with MSC derived from healthy donors (MSC-HD) and EWS cell lines. We evaluated the presence of the EWS-FLI1 gene fusion and EWSR1 gene rearrangements in MSC-P. The presence of the EWS transcript was confirmed by q-RT-PCR. In order to determine early events possibly involved in malignant transformation, we used a multiparameter quantitative strategy that included both MSC immunophenotypic negative/positive markers, and EWS intrinsic phenotypical features. Markers CD105, CD90, CD34 and CD45 were confirmed in EWS samples., [Results] We determined that MSC-P lack the most prevalent gene fusion, EWSR1-FLI1 as well as EWSR1 gene rearrangements. Our study also revealed that MSC-P are more alike to MSC-HD than to EWS cells. Nonetheless, we also observed that EWS cells had a few overlapping features with MSC. As a relevant example, also MSC showed CD99 expression, hallmark of EWS diagnosis. However, we observed that, in contrast to EWS cells, MSC were not sensitive to the inhibition of CD99. [Conclusions] In conclusion, our results suggest that MSC from EWS patients behave like MSC-HD and are phenotypically different from EWS cells, thus raising important questions regarding MSC role in sarcomagenesis. © 2014 Amaral et al., Enrique de Álava's lab is also sourced by the Red Temática de investigación del cáncer (RTICC, Spain). Katia Scotlandi's lab is also sourced by the Italian Association for cancer research (AIRC IG10452)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Correction: Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications

  • Amaral, Ana Teresa
  • Biscuola, Michele
  • López-García, María Ángeles
  • Álava, Enrique de
Amaral, Ana Teresa et al., [Background] Ewing Sarcoma (EWS) is a mesenchymal-derived tumor that generally arises in bone and soft tissue. Intensive research regarding the pathogenesis of EWS has been insufficient to pinpoint the early events of Ewing sarcomagenesis. However, the Mesenchymal Stem Cell (MSC) is currently accepted as the most probable cell of origin., [Materials and Methods] In an initial study regarding a deep characterization of MSC obtained specifically from EWS patients (MSC-P), we compared them with MSC derived from healthy donors (MSC-HD) and EWS cell lines. We evaluated the presence of the EWS-FLI1 gene fusion and EWSR1 gene rearrangements in MSC-P. The presence of the EWS transcript was confirmed by q-RT-PCR. In order to determine early events possibly involved in malignant transformation, we used a multiparameter quantitative strategy that included both MSC immunophenotypic negative/positive markers, and EWS intrinsic phenotypical features. Markers CD105, CD90, CD34 and CD45 were confirmed in EWS samples., [Results] We determined that MSC-P lack the most prevalent gene fusion, EWSR1-FLI1 as well as EWSR1 gene rearrangements. Our study also revealed that MSC-P are more alike to MSC-HD than to EWS cells. Nonetheless, we also observed that EWS cells had a few overlapping features with MSC. As a relevant example, also MSC showed CD99 expression, hallmark of EWS diagnosis. However, we observed that, in contrast to EWS cells, MSC were not sensitive to the inhibition of CD99., [Conclusions] In conclusion, our results suggest that MSC from EWS patients behave like MSC-HD and are phenotypically different from EWS cells, thus raising important questions regarding MSC role in sarcomagenesis. © 2014 Amaral et al., Research in Enrique de Alava's lab is supported by the Ministry of Science and Innovation of Spain-FEDER (PI081828, RD06/0020/0059, PI110018, ISCIII, postdoc grant CD06/00001 to JLOG), the Fundação para a Ciência e Tecnologia, Ministério para a Investigação e Tecnologia, Portugal (ATA fellowship SFRH/BD/69318/2010) and the Red Temática de investigación del cáncer (RTICC, Spain). This work was also supported by the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC). Katia Scotlandi's lab is also funded by AIRC, Italian Association for Cancer Research, (project 10452 to KS), Progetto FIRB- Accordi di programma 2010 COD, RBAP10447, and by the Italian Ministry of Health (Project IOR-2006-422755)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HMGA2 overexpression predicts relapse susceptibility of blastemal Wilms tumor patients

  • Hontecillas-Prieto, Lourdes
  • García-Domínguez, D. J.
  • García-Mejías, Rosa
  • Ramírez-Villar, Gema L.
  • Sáez, Carmen
  • Álava, Enrique de
Wilms tumor (WT) is an embryonal malignant neoplasm of the kidney that accounts for 6–7% of all childhood cancers. WT seems to derive from multipotent embryonic renal stem cells that have failed to differentiate properly. Since mechanisms underlying WT tumorigenesis remain largely unknown, the aim of this study was to explore the expression of embryonic stem cell (ESC) markers in samples of WT patients after chemotherapy treatment SIOP protocol, as the gene expression patterns of ESC are like those of most cancer cells. We found that expression of ESC markers is heterogeneous, and depends on histological WT components. Interestingly, among ESC markers, HMGA2 was expressed significantly stronger in the blastemal component than in the stromal and the normal kidney. Moreover, two subsets of patients of WT blastemal type were identified, depending on the expression levels of HMGA2. High HMGA2 expression levels were significantly associated with a higher proliferation rate (p=0.0345) and worse patient prognosis (p=0.0289). The expression of HMGA2 was a stage-independent factor of clinical outcome in blastemal WT patients. Our multivariate analyses demonstrated the association between LIN28B–LET7A–HMGA2 expression, and the positive correlation between HMGA2 and SLUG expression (p=0.0358) in blastemal WT components. In addition, patients with a poor prognosis and high HMGA2 expression presented high levels of MDR3 (multidrug resistance transporter). Our findings suggest that HMGA2 plays a prominent role in the pathogenesis of a subset of blastemal WT, strongly associated with relapse and resistance to chemotherapy., LHP and DJGD are supported by Red Temática de Investigación Cooperativa en Cáncer (RD12/0036/0017). CS is supported by a contract from Nicolás Monardes Program, Consejería de Salud, Junta de Andalucía. Research in Enrique de Alava’s lab is supported by the Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC, PI1700464, RD06/0020/0059, FMGE) and the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC). DJGD is a PhD researcher funded by the Consejería de Salud, Junta de Andalucía (PI-0197-2016). Research in Carmen Sáez’s lab is also supported by research grants from the Instituto de Salud Carlos III, FIS PI13/02282., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein

  • Hernández-Muñoz, Inmaculada
  • Figuerola-Bou, Elisabet
  • Sánchez-Molina, Sara
  • Rodríguez, Eva
  • Fernández-Maríño, A. I.
  • Pardo-Pastor, Carlos
  • Bahamonde, María Isabel
  • Fernández-Fernández, J. M.
  • García-Domínguez, D. J.
  • Hontecillas-Prieto, Lourdes
  • Lavarino, Cinzia
  • Carcaboso, Ángel M.
  • Torres, Carmen de
  • Tirado, Óscar M.
  • Álava, Enrique de
  • Mora, Jaume
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., IHM is a Miguel Servet investigator (Instituto de Salud Carlos III, ISCIII). This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MEC-FEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014-2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7-HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIII-FEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG-08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma

  • García-Domínguez, D. J.
  • Hontecillas-Prieto, Lourdes
  • Rodríguez-Núñez, Pablo
  • Pascual-Pasto, Guillem
  • Vila-Ubach, Mònica
  • García-Mejías, Rosa
  • Robles-Frías, María José
  • Tirado, Óscar M.
  • Mora, Jaume
  • Carcaboso, Ángel M.
  • Álava, Enrique de
[Purpose] Epigenetic regulation is crucial in mammalian development and maintenance of tissue-cell specific functions. Perturbation of epigenetic balance may lead to alterations in gene expression, resulting in cellular transformation and malignancy. Previous studies in Ewing sarcoma (ES) have shown that the Nucleosome Remodeling Deacetylase (NuRD) complex binds directly to EWS-FLI1 oncoprotein and modulates its transcriptional activity. The role of EWS-FLI1 as a driver of proliferation and transformation in ES is widely known, but the effect of epigenetic drugs on fusion activity remains poorly described. The present study evaluated the combination effects of the histone deacetylases inhibitor suberoylanilide hydroxamic acid (SAHA) and Lysine-specific demethylase1 inhibitor (HCI-2509) on different biological functions in ES and in comparison to monotherapy treatments., [Results] The study of proliferation and cell viability showed a synergistic effect in most ES cell lines analyzed. An enhanced effect was also observed in the induction of apoptosis, together with accumulation of cells in G1 phase and a blockage of the migratory capacity of ES cell lines. Treatment, either in monotherapy or in combination, caused a significant decrease of EWS-FLI1 mRNA and protein levels and this effect is mediated in part by fusion gene promoter regulation. The anti-tumor effect of this combination was confirmed in patient-derived xenograft mouse models, in which only the combination treatment led to a statistically significant decrease in tumor volume., [Conclusions] The combination of SAHA and HCI-2509 is proposed as a novel treatment strategy for ES patients to inhibit the essential driver of this sarcoma and tumor growth., Research in EDA, JM, and OMT labs is supported by Asociación Española Contra el Cáncer (AECC). Enrique de Alava’s lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC, PI11700464, RD06/0020/0059, FMGE) and the European Commission (FP7-HEALTH-2011-two-stage, Project ID278742 EUROSARC). DGD and LHP are supported by Red Temática de Investigación Cooperativa en Cáncer (RD12/0036/0017) and Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00361)S. PRN is supported by a grant from the María García Estrada Foundation. DGD is a PhD researcher funded by the Consejería de Salud, Junta de Andalucía (PI-0197-2016). MJR is supported by the Consejería de Salud, Junta de Andalucía (ECAIF2-0176-2013)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An inducible ectopic expression system of EWSR1-FLI1 as a tool for understanding Ewing sarcoma oncogenesis

  • García-Domínguez, D. J.
  • Hontecillas-Prieto, Lourdes
  • Andrés-León, Eduardo
  • Sánchez-Molina, Sara
  • Rodríguez-Núñez, Pablo
  • Morón, Francisco J.
  • Hajji, Nabil
  • Mackintosh, Carlos
  • Álava, Enrique de
The presence of the chimeric EWSR1-FLI1 oncoprotein is the main and initiating event defining Ewing sarcoma (ES). The dysregulation of epigenomic and proteomic homeostasis induced by the oncoprotein contributes to a wide variety of events involved in oncogenesis and tumor progression. Attempts at studying the effects of EWSR1-FLI1 in non-tumor cells to understand the mechanisms underlying sarcomagenesis have been unsuccessful to date, as ectopic expression of EWSR1-FLI1 blocks cell cycle progression and induces apoptosis in the tested cell lines. Therefore, it is essential to find a permissive cell type for EWSR1-FLI1 expression that allows its endogenous molecular functions to be studied. Here we have demonstrated that HeLa cell lines are permissive to EWSR1-FLI1 ectopic expression, and that our model substantially recapitulates the endogenous activity of the EWSR1-FLI1 fusion protein. This model could contribute to better understanding ES sarcomagenesis by helping to understand the molecular mechanisms induced by the EWSR1-FLI1 oncoprotein., Research in the EDA lab is supported by Asociación Española Contra el Cáncer (AECC). Enrique de Alava’s lab is also supported by the Ministry of Economy and Competitiveness of Spain-FEDER (CIBERONC, PI11700464, RD06/0020/0059) and the European Commission (FP7-HEALTH-2011-two-stage, Project ID278742 EUROSARC). DGD and LHP are supported by CIBERONC (CB16/12/00361). DGD is a PhD researcher funded by the Consejería de Salud, Junta de Andalucía (PI-0197-2016). LHP is a PhD researcher funded by the Consejería de Salud, Junta de Andalucía (PI-0013-2018). The funder Vitro SA provided support in the form of salaries for the author CM but had no additional roles in the study design, data collection, data analyses, decision to publish or manuscript preparation. The specific roles of this author (CM) are articulated in the ‘author contributions’ section.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trialmm

  • Martín-Broto, Javier
  • López-Álvarez, María
  • Moura, David S.
  • Ramos, Rafael
  • Collini, Paola
  • Romagosa, Cleofe
  • Bagué, Silvia
  • Renne, Salvatore L.
  • Barisella, Marta
  • Velasco, Valerie
  • Coindre, Jean-Michel
  • López-López, Daniel
  • Dopazo, Joaquín
  • Gambarotti, Marco
  • Braglia, Luca
  • Merlo, Domenico Franco
  • Palmerini, Emanuela
  • Stacchiotti, Silvia
  • Quagliuolo, Vittorio L.
  • López-Pousa, Antonio
  • Grignani, Giovanni
  • Blay, Jean-Yves
  • Brunello, Antonella
  • Gutiérrez, Antonio
  • Valverde, Claudia M.
  • Hindi, Nadia
  • Dei Tos, Angelo Paolo
  • Picci, Piero
  • Casali, Paolo G.
  • Gronchi, Alesandro
MRP-1 is implicated in multidrug resistance and was described as prognostic in high-risk patients with soft-tissue sarcoma (STS) in a previous study. The current research aimed to validate MRP-1 prognostic/predictive value in localized sarcomas treated with anthracyclines plus ifosfamide within the ISG-1001 phase III study. In addition, the inhibitory activity on MRP-1 was investigated in preclinical studies to identify new combinations able to increase the efficacy of standard chemotherapy in STS. MRP-1 expression was assessed by IHC in tissue microarrays from patients with STS and tested for correlation with disease-free survival (DFS) and overall survival (OS). In vitro studies tested the efficacy of MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, and avapritinib) in sarcoma cell lines. The effect of combinations of the most active MRP-1 inhibitors and chemotherapy was measured on the basis of apoptosis. MRP-1 was evaluable in 231 of 264 cases who entered the study. MRP-1 expression (strong intensity) was independently associated with worse DFS [HR, 1.78; 95% confidence interval (CI), 1.11–2.83; P = 0.016], in the multivariate analysis, with a trend for a worse OS (HR, 1.78; 95% CI, 0.97–3.25; P = 0.062). In vitro studies showed that the addition of MRP-1 inhibitors (nilotinib or avapritinib) to doxorubicin plus palifosfamide, significantly increased cell death in SK-UT-1 and CP0024 cell lines. MRP-1 is an adverse predictive factor in localized high-risk patients with STS treated with neoadjuvant anthracyclines plus ifosfamide followed by surgery. In vitro findings support the clinical assessment of the combination of chemotherapy and MRP-1 inhibitors as a promising strategy to overcome the drug ceiling effect for chemotherapy., The study was partially funded through a European Union grant (EUROSARC FP7 278472). The authors would like to thank Patricio Ledesma Figueroa for Data Management. J. Martin-Broto, D.S. Moura and N. Hindi would like to thank the International Accelerator Award funded by Cancer Research UK [C56167/A29363], Associazione Italiana per la Ricerca sul Cancro [AIRC - 24297] and Fundacion Científica – Asociacion Espanola Contra el Cancer [Foundation AECC - GEACC19007MA]. D.S. Moura was supported by a Sara Borrell grant (CD20/00155) funded by the Instituto de Salud Carlos III. C. Romagosa was supported by a grant from the “Programa d'impuls del talent i de l'ocupabilitat del PERIS 2016–2020.” J-Y. Blay would like to express gratitude for the support from NetSARC (INCA and DGOS) EURACAN (EC 739521) and LYRICAN (INCA-DGOS-INSERM 12563). The ISH1001 study was supported by Eurosarc (FP7–278742).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

  • Kager, Leo
  • Whelan, Jeremy
  • Dirksen, Uta
  • Hassan, Bass
  • Anninga, Jakob
  • Bennister, Lindsey
  • Bovée, Judith V. M. G.
  • Brennan, Bernadette
  • Broto, Javier Martín
  • Brugières, Laurence
  • Cleton-Jansen, Anne-Marie
  • Copland, Christopher
  • Dutour, Aurélie
  • Fagioli, Franca
  • Ferrari, Stefano
  • Fiocco, Marta
  • Fleuren, Emmy
  • Gaspar, Nathalie
  • Gelderblom, Hans
  • Gerrand, Craig
  • Gerß, Joachim
  • Gonzato, Ornella
  • van der Graaf, Winette
  • Hecker-Nolting, Stefanie
  • Herrero Martín, David
  • Klco-Brosius, Stephanie
  • Kovar, Heinrich
  • Ladenstein, Ruth
  • Lancia, Carlo
  • LeDeley, Marie-Cecile
  • McCabe, Martin G.
  • Metzler, Markus
  • Myklebost, Ola
  • Nathrath, Michaela
  • Picci, Piero
  • Potratz, Jenny
  • Redini, Françoise
  • Richter, Günther H. S.
  • Reinke, Denise
  • Rutkowski, Piotr
  • Scotlandi, Katia
  • Strauss, Sandra
  • Thomas, David
  • Tirado, Oscar M.
  • Tirode, Franck
  • Vassal, Gilles
  • Bielack, Stefan S.
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.

  • Hernández-Muñoz, Inmaculada
  • Figuerola, Elisabeth
  • Sánchez-Molina, Sara
  • Rodríguez García, Eva
  • Fernández Mariño, Ana Isabel, 1984-
  • Pardo-Pastor, Carlos
  • Bahamonde Santos, María Isabel, 1972-
  • Fernández-Fernández, José Manuel, 1967-
  • García-Domínguez, Daniel J.
  • Hontecillas-Prieto, Lourdes
  • Lavarino, Cinzia
  • Carcaboso, Angel M.
  • Torres, Carmen de
  • Tirado, Oscar M.
  • Alava, Enrique de
  • Mora, Jaume
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MECFEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014- 2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7- HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIIIFEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG- 08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation.
GREDOS. Repositorio Institucional de la Universidad de Salamanca
Publicación Artículo científico (JournalArticle)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

  • Ordóñez García, José Luis
  • Amaral, Ana Teresa
  • Carcaboso, Angel M.
  • Herrero Martín, David
  • García-Macías, María del Carmen
  • Sevillano, Vicky
  • Alonso López, Diego
  • Pascual-Pasto, Guillem
  • San-Segundo, Laura
  • Vila-Ubach, Monica
  • Rodrígues, Telmo
  • Fraile Martín, Susana
  • Teodosio, Cristina
  • Mayo-Iscar, Agustín
  • Aracil, Miguel
  • Galmarini, Carlos María
  • Tirado, Oscar M.
  • Mora, Jaume
  • de Álava Casado, Enrique
José Luis Ordóñez disfrutó de una beca JAE-DOC financiada por el CSIC y el European Social Fund y por la AECC, [EN] Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors (PARPinh) in combination with DNA damage repair (DDR) agents. Trabectedin is an antitumoral agent that modulates EWSR1-FLI1 transcriptional functions, causing DNA damage. Interestingly, PARP1 is also a transcriptional regulator of EWSR1-FLI1, and PARPinh disrupts the DDR machinery. Thus, given the impact and apparent specificity of both agents with regard to the DNA damage/DDR system and EWSR1-FLI1 activity in ES, we decided to explore the activity of combining PARPinh and Trabectedin in in vitro and in vivo experiments. The combination of Olaparib and Trabectedin was found to be highly synergistic, inhibiting cell proliferation, inducing apoptosis, and the accumulation of G2/M. The drug combination also enhanced γH2AX intranuclear accumulation as a result of DNA damage induction, DNA fragmentation and global DDR deregulation, while EWSR1-FLI1 target expression remained unaffected. The effect of the drug combination was corroborated in a mouse xenograft model of ES and, more importantly, in two ES patient-derived xenograft (PDX) models in which the tumors showed complete regression. In conclusion, the combination of the two agents leads to a biologically significant deregulation of the DDR machinery that elicits relevant antitumor activity in preclinical models and might represent a promising therapeutic tool that should be further explored for translation to the clinical setting., The Ministry of Economy and Competitiveness of Spain-FEDER (PI081828, RD06/0020/0059 RD12/0036/0017, PT13/0010/0056, PI110018, ISCIII Sara Borrell postdoc grant CD06/00001) The European Project EuroSARC (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC), Fundación Memoria de D. Manuel Solorzano Barruso, Fundación Cris contra el cancer, and Fundación María García Estrada. JLO was sponsored by the CSIC and the European Social Fund (post-doctoral grant JAE DOC) and is at present funded by the AECC. ATA is sponsored by the Fundaçao para a Ciência e Tecnologia, Portugal (fellowship SFRH/BD/69318/2010). OMT is funded by Fondo de Investigaciones Sanitarias-ISCIII (CES12/021) and the AECC. DHM is funded by the AECC. Work supported by the Xarxa de Bancs de Tumors de Catalunya (XBTC) sponsored by Pla Director d’Oncologia de Catalunya. AMC acknowledges funding from the European Union Seventh Framework Programme (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG-08-GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group of HSJ’s laboratory is supported by generous donations from the Pablo Ugarte foundation.
GREDOS. Repositorio Institucional de la Universidad de Salamanca
Publicación Artículo científico (JournalArticle)

WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells

  • Mackintosh Ginel, Carlos Jesús
  • García Domínguez, Daniel José
  • Ordóñez García, José Luis
  • Ginel Picardo, Alicia
  • Smith, P. G.
  • Sacristán Martín, María Paz
  • de Álava Casado, Enrique
[EN]Ewing sarcoma (ES) is an aggressive bone and soft tissue tumor of children and young adults in which finding effective new targeted therapies is imperative. Here, we report an in-depth preclinical study of the investigational cullin-RING ubiquitin ligase (CRL) inhibitor MLN4924 in ES, as we have recently demonstrated the implication of a CRL component in the ES pathogenesis. First, our results support a high sensitivity of ES cells to MLN4924 growth inhibition both in vitro (14 ES cell lines tested, median IC50¼81 nM) and in tumor xenografts (tumor regression achieved with 60 mg/kg BID, subcutaneously, n¼9). Second, we report a dual mechanism of action of MLN4924 in ES cells: while a wide range of MLN4924 concentrations (B30–300 nM) trigger a G2 arrest that can only be rescued by WEE1 kinase inhibition or depletion, saturating doses of the drug (4300 nM) cause a delay in S-phase progression concomitant with unbalanced CDK2-Cyclin E and CDK2-Cyclin A relative levels (accumulation of the first and depletion of the latter). The aberrant presence of CDC6 in the nucleus at late S-phase cell cycle stage confirmed the loss of CDK2-Cyclin A-specific functions. Remarkably, other mechanisms explored (P27 accumulation and DNA damage signaling pathways) were found unable to explain MLN4924 effects, strengthening the specificity of our findings and suggesting the absence of functionality of some CRL substrates accumulated in response to MLN4924. This study renders a rationale for clinical trials and contributes molecular mechanisms for a better understanding of this promising antitumoral agent., Ministry of Economy and Competitiveness of Spain-FEDER (PI081828, RD06/0020/0059, PI1100018, ISCIII_postdoc grant CD06/00001) European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC Furndación María García Estrada
GREDOS. Repositorio Institucional de la Universidad de Salamanca
Publicación Artículo científico (JournalArticle)

Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications

  • Amaral, Ana Teresa
  • Manara, María Cristina
  • Berghuis, Dagmar
  • Ordóñez García, José Luis
  • Biscuola, Michele
  • López-García, María Angeles
  • Osuna, Daniel
  • Lucarelli, Enrico
  • Alviano, Francesco
  • Lankester, Arjan
  • Scotlandi, Katia
  • de Álava Casado, Enrique
Research in Enrique de Alava's lab is supported by the Ministry of Science and Innovation of Spain-FEDER (PI081828, RD06/0020/0059, PI110018, ISCIII, postdoc grant CD06/00001 to JLOG), the Fundação para a Ciência e Tecnologia, Ministério para a Investigação e Tecnologia, Portugal (ATA fellowship SFRH/BD/69318/2010) and the Red Temática de investigación del cáncer (RTICC, Spain). This work was also supported by the European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC). Katia Scotlandi's lab is also funded by AIRC, Italian Association for Cancer Research, (project 10452 to KS), Progetto FIRB- Accordi di programma 2010 COD, RBAP10447, and by the Italian Ministry of Health (Project IOR-2006-422755), [EN] Ewing Sarcoma (EWS) is a mesenchymal-derived tumor that generally arises in bone and soft tissue. Intensive research regarding the pathogenesis of EWS has been insufficient to pinpoint the early events of Ewing sarcomagenesis. However, the Mesenchymal Stem Cell (MSC) is currently accepted as the most probable cell of origin. Materials and Methods: In an initial study regarding a deep characterization of MSC obtained specifically from EWS patients (MSC-P), we compared them with MSC derived from healthy donors (MSC-HD) and EWS cell lines. We evaluated the presence of the EWS-FLI1 gene fusion and EWSR1 gene rearrangements in MSC-P. The presence of the EWS transcript was confirmed by q-RT-PCR. In order to determine early events possibly involved in malignant transformation, we used a multiparameter quantitative strategy that included both MSC immunophenotypic negative/positive markers, and EWS intrinsic phenotypical features. Markers CD105, CD90, CD34 and CD45 were confirmed in EWS samples. Results: We determined that MSC-P lack the most prevalent gene fusion, EWSR1-FLI1 as well as EWSR1 gene rearrangements. Our study also revealed that MSC-P are more alike to MSC-HD than to EWS cells. Nonetheless, we also observed that EWS cells had a few overlapping features with MSC. As a relevant example, also MSC showed CD99 expression, hallmark of EWS diagnosis. However, we observed that, in contrast to EWS cells, MSC were not sensitive to the inhibition of CD99. Conclusions: In conclusion, our results suggest that MSC from EWS patients behave like MSC-HD and are phenotypically different from EWS cells, thus raising important questions regarding MSC role in sarcomagenesis. © 2014 Amaral et al., Ministry of Science and Innovation of Spain-FEDER Fundação para a Ciência e Tecnologia, Ministério para a Investigação e Tecnologia, Portugal Red Temática de investigación del cáncer (RTICC, Spain). European Commission (FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC).
GREDOS. Repositorio Institucional de la Universidad de Salamanca
Publicación Artículo científico (JournalArticle)

Trabectedin efficacy in Ewing sarcoma Is greatly increased by combination with anti-IGF signaling agents

  • Amaral, Ana Teresa
  • Garofalo, Cecilia
  • Frapolli, Roberta
  • Manara, María Cristina
  • Mancarella, Caterina
  • Uboldi, Sarah
  • Giandomenico, Silvana Di
  • Ordóñez García, José Luis
  • Sevillano, María Victoria
  • Malaguarnera, Roberta
  • Picci, Piero
  • Hassan, A. Bass
  • de Álava Casado, Enrique
  • D'Incalci, Maurizio
  • Scotlandi, Katia
[EN]Purpose: Goal of this study was to identify mechanisms that limit efficacy of trabectedin (ET-743, Yondelis) in Ewing sarcoma (EWS), so as to develop a clinical applicable combination therapy. Experimental Design: By chromatin immunoprecipitation, we analyzed EWS-FLI1 binding to the promoters of several target genes, such as TGFβR2, CD99, insulin-like growth factor receptor 1 (IGF1R), and IGF1, both in vitro and in xenografts treated with trabectedin or doxorubicin. Combined therapy with trabectedin and anti-IGF1R agents (AVE1642 HAb; OSI-906) was tested in vitro and in xenografts. Results: We confirm that both trabectedin and doxorubicin were able to strongly reduce EWS-FLI1 (both type I and type II) binding to two representative target genes ( TGFβR2 and CD99), both in vitro and in xenografts. However, trabectedin, but not doxorubicin, was also able to increase the occupancy of EWS-FLI1 to IGF1R promoters, leading to IGF1R upregulation. Inhibition of IGF1R either by the specific AVE1642 human antibody or by the dual IGF1R/insulin receptor inhibitor OSI-906 (Linsitinib) greatly potentiate the efficacy of trabectedin in the 13 EWS cell lines here considered as well as in TC-71 and 6647 xenografts. Combined therapy induced synergistic cytotoxic effects. Trabectedin and OSI-906 deliver complementary messages that likely converge on DNA-damage response and repair pathways. Conclusions: Weshowed that trabectedin may not only inhibit but also enhance the binding of EWS-FLI1 to certain target genes, leading to upregulation of IGF1R. We here provide the rationale for combining trabectedin to anti-IGF1R inhibitors., This work was financially supported by the EU project FP7-HEALTH-2011-two-stage, Project ID 278742 EUROSARC; the Italian Association for Cancer Research (Katia Scotlandi—AIRC Project N.14049; C. Garofalo—MFAG N.11584 and M. D'Incalci—AIRC Project N.14658); The Italian Ministry of Research and Education (F.I.R.B. project number: RBAP11884M_005); The Italian Ministry of the Health (67/GR-2010-2319511, CUP G71J12000830001). E. de Álava's laboratory is supported by the AECC (Asociación Española contra el Cáncer), the Ministry of Economy and Competitivity of Spain-FEDER (PI081828, RD06/0020/0059 RD12/0036/0017, PT13/0010/0056, PI110018, ISCIII Sara Borrell postdoc grant CD06/00001), and Fundación Memoria de D. Manuel Solorzano Barruso, Fundación Cris contra el cancer, and Fundación María García Estrada. J.L. Ordóñez is sponsored by the CSIC and the European Social Fund (postdoctoral grant JAE DOC), A.T. Amaral is sponsored by the Fundaçao para a Ciência e Tecnologia, Portugal (fellowship SFRH/BD/69318/2010); and S. Uboldi is recipient of a FIRC Fellowship N.13743.